Secondary Neoplasm

In patients with Barrett's adenocarcinoma, those with amplification of EGFR had shorter disease-specific survial.

PMID 20840671 · Marx et al., 2010 · Open in CIViC

In patients with cervical squamous cell carcinoma, those with gene amplification of EGFR had worse overall survival.

PMID 21730982 · Iida et al., 2011 · Open in CIViC

This retrospective analysis of a Phase 2 trial shows significant association between increased EGFR gene copy number (≥ 4.0) and overall survival (OS) in patients with gastric and oesophago-gastric ju… (full text at CIViC)

PMID 22152101 · Luber et al., 2011 · Open in CIViC

This retrospective preclinical study assessed the efficacies of cetuximab, afatinib, and erlotinib towards head and neck squamous cell carcinoma (HNSCC) & esophageal squamous cell carcinoma (ESCC) cel… (full text at CIViC)

PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

EGFR amplification was not a predictor of response to cetuximab/5-FU/platinum in patients with recurrent or metastatic HNSSC from the EXTREME study.

PMID 21048039 · Licitra et al., 2011 · Open in CIViC

A case report of a 49 year old female with gastric signet ring cell carcinoma, in whom a genomic screen of cf tumour DNA revealed an EGFR::SEPT14 fusion at a VAF of 45.3%. The fusion was confirmed by … (full text at CIViC)

PMID 33969073 · Kim et al., 2021 · Open in CIViC

Case report describing a 63-year-old patient with colorectal adenocarcinoma. He started treatment with XELOX and bevacizumab. After findings of disease progression, they changed to bevacizumab and FOL… (full text at CIViC)

PMID 32162810 · Li et al., 2020 · Open in CIViC

The ctDNA of 46 patients with hepatocellular carcinoma was analyzed to investigate whether EGFR alterations could lead to lenvatinib resistance. Among these patients, 16 had been treated with lenvatin… (full text at CIViC)

PMID 36708791 · Lim et al., 2023 · Open in CIViC

A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R+T790M transgene. Twenty of 49 mice treated with osimertinib developed treatment-resistant tum… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. A set of osimertinib resistant tumours were treated with 25mg/kg osimertinib and 2… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. Mice were treated with either daily 5mg/kg, followed by 25mg/kg after tumour recur… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

In 134 patients with head and neck squamous cancer 32 had copy number variations. Tumors with variation (either increase or decrease) in copy number of EGFR had worse overall, cancer-specific, and dis… (full text at CIViC)

PMID 17538160 · Temam et al., 2007 · Open in CIViC

In a study of 19 non-small cell lung carcinoma patients with EGFR exon 20 insertion mutation and treated with erlotinib monotherapy, patients with EGFR D770delinsGY mutation (n=2) experienced progress… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

2 patients with EGFR D770_N771insGL mutant lung adenocarcinoma were treated with first line erlotinib. A 45 year old male never smoker had progressive disease as best response with +24% change to tar… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

In a lung adenocarcinoma patient harboring EGFR D770_N771insGT mutation, EGFR D770_N771insGT was associated with lack of response to treatment with erlotinib monotherapy.

PMID 23371856 · Arcila et al., 2013 · Open in CIViC

In a stage IV lung adenocarcinoma patient with EGFR E709_T710>D mutation, EGFR E709_T710>D was reported to be sensitive to erlotinib treatment. The patient was treated with erlotinib monotherapy and a… (full text at CIViC)

PMID 22982663 · Ackerman et al., 2012 · Open in CIViC

EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib in a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma). One patient … (full text at CIViC)

PMID 15329413 · Pao et al., 2004 · Open in CIViC

In a Taiwanese stage IV lung adenocarcinoma patient with brain metastasis harboring EGFR E746_A750del mutation, EGFR E746_A750del was reported to be sensitive to erlotinib treatment. The patient was t… (full text at CIViC)

PMID 17618013 · Chang et al., 2007 · Open in CIViC

A study of five clinical trials reported that chemotherapy na�ve non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib o… (full text at CIViC)

PMID 19671843 · Jackman et al., 2009 · Open in CIViC

In a meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, one patient was described with the exon 19 mutation E746G from the BeTa study. Progression-free (415 days) and overall (46… (full text at CIViC)

PMID 26773740 · Klughammer et al., 2016 · Open in CIViC

In a lung adenocarcinoma patient with EGFR E746_T751>A mutation EGFR E746_A751>A was associated with improved response to erlotinib treatment. The patient was treated with erlotinib monotherapy and ac… (full text at CIViC)

PMID 17085664 · Balak et al., 2006 · Open in CIViC

Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen lung cancer patients who had shown partial response or clinical imporvement in response to gefitinib. O… (full text at CIViC)

PMID 15329413 · Pao et al., 2004 · Open in CIViC

In a lung adenocarcinoma patient harboring EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitor) and EGFR E884K co-mutations, EGFR E884K was reported to be refractory to erlotini… (full text at CIViC)

PMID 16407879 · Choong et al., 2006 · Open in CIViC

Case report describing a 63-year-old patient with colorectal adenocarcinoma with disease progression after treatment with XELOX-bevacizumab and bevacizumab-FOLFIRI. After the detection of EGFR aberrat… (full text at CIViC)

PMID 32162810 · Li et al., 2020 · Open in CIViC

This is a case report of a 58-year-old never-smoker diagnosed with metastatic lung adenocarcinoma. The patient was treated with multiple lines of chemotherapy ((1) carboplatin/pemetrexed, (2)docetaxel… (full text at CIViC)

PMID 39637337 · Guimaraes-Young et al., 2024 · Open in CIViC

A phase III clinical trial (NCT00949650) found that median progression free survival among patients with EGFR exon 19 deletion was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 9… (full text at CIViC)

PMID 23816960 · Sequist et al., 2013 · Open in CIViC

Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364… (full text at CIViC)

PMID 24439929 · Wu et al., 2014 · Open in CIViC

A 53-year old woman (former smoker: 15 pack-years) was diagnosed with non-small-cell lung cancer that revealed an adenocarcinoma. Initial tumor was sequenced to find an EGFR exon 19 deletion mutation … (full text at CIViC)

PMID 30341016 · Kauffmann-Guerrero et al., 2019 · Open in CIViC

A 65-year old female diagnosed with lung adenocarcinoma revealed several brain lesions, the largest measuring 1.8 x 1.5 x 1.9 cm. COBAS EGFR mutation test was run and revealed EGFR exon 19 deletion mu… (full text at CIViC)

PMID 36188633 · Wilgucki et al., 2022 · Open in CIViC

In retrospective analysis of trials, afatinib conferred limited clinical benefit to patients with EGFR exon 20 insertion mutations (N=23). Only 2 patients had objective responses.

PMID 26051236 · Yang et al., 2015 · Open in CIViC

A retrospective study showed that out of 11 patients with stage IV lung adenocarcinoma treated with erlotinib who carried in-frame exon 20 insertion variant, only 3 patients showed objective response … (full text at CIViC)

PMID 26096453 · Naidoo et al., 2015 · Open in CIViC

A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 del… (full text at CIViC)

PMID 21969500 · Brugger et al., 2011 · Open in CIViC

In a meta-analysis of 7 clinical trials of erlotinib (some vs placebo or other treatment), 10/24 patients with Exon 18 mutations harbored a G719 variant. These variants were associated with improved p… (full text at CIViC)

PMID 26773740 · Klughammer et al., 2016 · Open in CIViC

In a retrospective study of 46, Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR G719A mutation was associated with resistance to erlotinib treatment. The patient survived 9.… (full text at CIViC)

PMID 27032107 · De Grève et al., 2016 · Open in CIViC

A 60-year old man (smoker: 300 pack-years) presented with lung adenocarcinoma measuring 3.0 x 2.3 cm and multiple lymph node metastases. Next-generation sequencing revealed a EGFR G719A (abundance 5.0… (full text at CIViC)

PMID 30922580 · Zeng et al., 2019 · Open in CIViC

A patient with stage IV lung squamous cell carcinoma harboring an EGFR G719C mutation and high PD-L1 expression (tumor proportion score of 90%) experienced disease progression after 1.5 months of afat… (full text at CIViC)

PMID 40959071 · Fu et al., 2025 · Open in CIViC

In an advanced lung adenocarcinoma patient harboring EGFR G719S mutation, EGFR G719S was reported to be sensitive to erlotinib treatment. The patient was initially treated with standard chemotherapy, … (full text at CIViC)

PMID 21841502 · De Pas et al., 2011 · Open in CIViC

A 58-year-old male with stage IVB lung adenocarcinoma presented with respiratory symptoms and widespread metastases. NGS revealed EGFR-GNAT3 fusion (EGFR exons 1–24 to GNAT3 exon 8; 76.3% abundance) a… (full text at CIViC)

PMID 38595815 · Wang et al., 2024 · Open in CIViC

A 61 year old male never smoker with EGFR H773_V774insNPH mutant lung adenocarcinoma was treated with fourth line erlotinib and had progressive disease as best response, progression free survival of 1… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC